Skip to content

Mingjing Granule in the treatment of neovascular age-related macular degeneration: a prospective, randomized, double-blind, placebo parallel controlled, multicenter clinical trial

Mingjing Granule in the treatment of neovascular age-related macular degeneration: a prospective, randomized, double-blind, placebo parallel controlled, multicenter clinical trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003625
Enrollment
Unknown
Registered
2020-08-21
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular age-related macular degeneration

Interventions

Sponsors

Eye Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Exudative changes due to active CNV lesions secondary to AMD in one eye or both eyes. ? Up to the syndrome of TCM: Yin deficiency and blood stasis. ? Aged 50 to 80 years. ? The BCVA between 73 and 34 assessed by ETDRS charts(approximately 20/40-20/200 Snellen equivalent). ? Agree to participate in the trial and provide written informed consent.

Exclusion criteria

Exclusion criteria: ?Those with PCV or complete scars due to AMD but without bleeding or exudation. ?Those with high myopia, glaucoma, diabetic retinopathy, retinal vein occlusion, retinal artery occlusion, optic neuropath (optic neuritis, atrophy, papillary edema), macular hole or CNV due to other ocular fundus diseases; or with severe diseases in cardio-cerebrovessels, liver, hematopoietic systems, or severely life-threatening primary diseases or mental illness. ?Unclear dioptric media in the study eye that affecting ocular fundus examination. ?Those with creatinine the upper limit of normal, AST and/or ALT 2-fold the upper limitation of normal or above. ?Previous or concomitant participation in another clinical study with investigational medicinal products or combined with similar Chinese medicine or other therapies(prior treatment of the study eye with intraocular anti-VEGF agents, corticosteroids, laser, eye surgery within 3 months prior to study entry). ?Patients who the investigators deem to be ineligible for the study, such as unstable living environment, which may lead to loss of follow-up.

Design outcomes

Primary

MeasureTime frame
Best corrected visual acuity;

Secondary

MeasureTime frame
Central retinal thickness;Area of retinal hemorrhage and exudation;Total cost of the treatment;TCM syndrom score;The number of intravitreal ranibizumab injections;

Countries

China

Contacts

Public ContactLina Liang

Eye Hospital, China Academy of Chinese Medical Sciences

lianglina163@163.com+86 010-68683451

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026